News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Portola Pharmaceuticals, Inc. Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis


1/13/2014 9:41:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa* (PRT4445), with the oral Factor Xa inhibitor Eliquis® (apixaban). The original agreement, announced in November 2012, covered the conduct of a Phase 2 proof-of-concept study. Results of the Phase 2 study were presented at the 2013 Congress of the International Society on Thrombosis and Haemostasis (ISTH) and demonstrated andexanet alfa's ability to produce an immediate and either temporary or sustained reversal of the anticoagulation activity of Eliquis. The new clinical collaboration agreement will be in effect through Phase 3 studies with Eliquis and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES